Testing an IV antibiotic in people with kidney problems
Part of Infections clinical trials.
This study tests an IV antibiotic (cefiderocol/xeruborbactam) in people with different levels of kidney function, including those on dialysis. It aims to see how the drug is processed by the body and whether it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your kidney function falls into one of these groups: normal, mild to severe impairment (not on dialysis), or end-stage kidney disease on regular hemodialysis.
- Your body mass index (BMI) is between 18.5 and 45.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have no history of seizures, convulsions, or cancer (except some skin cancers).
- You are willing to avoid alcohol, caffeine, grapefruit, and certain medications before and during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new experimental drug (INCB123667) works and is tolerated in adults with severe kidney problems or end-stage kidney disease. Researchers want to understand how the drug moves through the body and whether it's safe for people in your situation.
This trial studies how common antibiotics move through the body when someone is on kidney replacement therapy (dialysis), including when dialysis starts during treatment. The results may help doctors choose the right antibiotic dose and timing for better infection treatment.
This trial tests a new antibiotic called ceftibuten-ledaborbactam in healthy volunteers to see if it is safe and how the body processes it. You may join if you are a healthy adult and do not have allergies to certain antibiotics.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This study tests a new combination of two antibiotics (meropenem and pralurbactam) given through an IV to treat serious abdominal infections. It is for adults who need hospital care and might be helped by a stronger infection-fighting drug.
This trial studies how the body handles the antibiotic afabicin in people with different levels of kidney function. It will help determine if the dose needs to be adjusted for people with kidney problems.
Hear when a new Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.